Abstract: The invention relates to the field of medicine and pharmaceuticals and particularly to a novel dosage form of an antitumor preparation, which ensures the hydrolytic and physical stability of said preparation, as well as to a method for producing a dosage form of this type. The stable dosage form is a lyophilizate comprising an etidronate-cytarabine conjugate or a pharmaceutically acceptable salt thereof, and a stabilizer, which is a divalent metal salt, in a molar ratio of stabilizer to conjugate of 1:1 to 20:1. A dosage form of this type ensures the hydrolytic and physical stability of the conjugate during long-term storage, and the stability of solutions of the conjugate for parenteral administration during clinical use.

Abstract: This invention relates to oncology, and specifically to a novel medicinal drug and a method for treating bone lesions caused by malignant neoplasms. A medicinal drug that represents a lyophilisate for solution for parenteral administration, including the following components: pharmaceutically acceptable salt of the divalent metal and 1-((((((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidine-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy))(hydroxy)phosphoryloxy)(hydroxy)phosphoryl)-1-hydroxyethylphosphonic acid or pharmaceutically acceptable salt hereof with a molar ratio of the components ranging from 1:1 to 20:1 is proposed for this purpose. The treatment method includes the drug solution administration according to the invention in the form of intravenous drop infusions in a dose ranging from 0.01 to 5 mg/kg of the active component per 1 kg of the patient's weight in the form of intravenous drop infusions.

Abstract: This invention relates to oncology, and specifically to a novel medicinal drug and a method for treating bone lesions caused by malignant neoplasms. A medicinal drug that represents a lyophilisate for solution for parenteral administration, including the following components: pharmaceutically acceptable salt of the divalent metal and 1-((((((2R,3S,4S,5R)-5-(4-amino-2- oxopyrimidine-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy))(hydroxy)phosphoryloxy)(hydroxy)phosphoryl)-1-hydroxyethylphosphonic acid or pharmaceutically acceptable salt hereof with a molar ratio of the components ranging from 1:1 to 20:1 is proposed for this purpose. The treatment method includes the drug solution administration according to the invention in the form of intravenous drop infusions in a dose ranging from 0.01 to 5 mg/kg of the active component per 1 kg of the patient's weight in the form of intravenous drop infusions.

Abstract: The invention relates to the field of medicine and pharmaceuticals and particularly to a novel dosage form of an antitumor preparation, which ensures the hydrolytic and physical stability of said preparation, as well as to a method for producing a dosage form of this type. The stable dosage form is a lyophilizate comprising an etidronate-cytarabine conjugate or a pharmaceutically acceptable salt thereof, and a stabilizer, which is a divalent metal salt, in a molar ratio of stabilizer to conjugate of 1:1 to 20:1. A dosage form of this type ensures the hydrolytic and physical stability of the conjugate during long-term storage, and the stability of solutions of the conjugate for parenteral administration during clinical use.